Jazz Pharmaceuticals Expects $755M IPR&D Charge and $11 EPS Hit in Q3 2026

Summary of Event

On October 26, 2026, Jazz Pharmaceuticals plc filed a Current Report on Form 8-K under Item 2.02 (Results of Operations and Financial Condition) detailing preliminary estimated financial impacts for the third quarter of 2026 resulting from its acquisition of Actio Biosciences, Inc.

Key Financial Highlights

• Acquisition Completion: The acquisition of Actio Biosciences, Inc. was completed on September 15, 2026.
• Acquired IPR&D Expense: Jazz Pharmaceuticals estimates GAAP and non-GAAP results for Q3 2026 will include a pre-tax charge of approximately $755 million in acquired in-process research and development (IPR&D).
• Tax & EPS Impact: The charge is not tax-deductible and is projected to negatively impact both GAAP diluted EPS and non-GAAP adjusted EPS by approximately $11.00 per share in the third quarter of 2026.
• Status: Results remain preliminary and subject to final financial closing procedures for the quarter ended September 30, 2026.

Market Implications

• Earnings Perception: While acquired IPR&D is a standard accounting treatment following biotech asset purchases, the magnitude (~$755M / ~$11.00 per share) represents a significant headline impact for Q3 2026 performance figures.
• Cash Flow Consideration: Acquired IPR&D reflects accounting allocation of purchase price to in-process assets without alternative future use rather than an ongoing operational cash expense.